Target intelligence / Profile preview

Inhibin beta E chain (INHBE)

Target
INHBE
Molecular classification
Other, Growth factor, Cytokine
01

Overview

Inhibin beta E chain (INHBE) is a member of the transforming growth factor-beta (TGF-beta) superfamily of proteins that is predominantly expressed in the liver and encodes the beta-E subunit, which homodimerizes to form the biologically active hepatokine Activin E. Activin E acts as a ligand that binds to ALK7 (ACVR1C) receptors on adipocytes, activating SMAD2/3 signaling to suppress lipolysis and promote lipid storage and fat accumulation. Human genetic studies have shown that individuals with loss-of-function mutations in the INHBE gene exhibit healthier fat distribution, improved metabolic profiles, and a lower risk of type 2 diabetes and coronary heart disease. Consequently, INHBE has emerged as a highly promising therapeutic target for the treatment of obesity, overweight, and metabolic dysfunction-associated steatohepatitis (MASH). Therapeutic strategies under development primarily utilize liver-directed small interfering RNAs (siRNAs), such as ARO-INHBE, IBI3046, RBD3133, and CMS-D008, to selectively silence hepatic INHBE expression. By reducing circulating Activin E levels, these therapies relieve the inhibition of lipolysis, promoting fat-selective weight loss while preserving lean muscle mass, either as monotherapies or in combination with GLP-1 receptor agonists.

Other names
Inhibin subunit beta EActivin beta-E chainActivin EInhibin beta E
02

Mechanism of action

RNA interference (RNAi) mediated gene silencing of hepatic INHBE expression to reduce circulating Activin E levels, thereby blocking Activin E-ALK7 signaling, increasing lipolysis, and reducing fat accumulation.

03

Biological functions

Signal transductionCell proliferationOtherLipid metabolic processEnergy homeostasis
04

Disease associations

Cardiovascular diseaseOtherObesityType 2 diabetesMetabolic dysfunction-associated steatohepatitis (MASH)
05

Safety considerations

Injection site reactionsPotential off-target effects of RNAiLong-term effects of systemic Activin E suppressionImmunogenicity
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

Activin E protein levelsBody weightBody composition (fat mass vs. lean mass)Liver fat contentVisceral fat volume

Beyond the preview

Go deeper on Inhibin beta E chain (INHBE).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inhibin beta E chain (INHBE).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call